Company intelligence / Profile preview

IMMIOS

Not specified, Not specified, Netherlandsimmios-biotech.com ↗

Ownership: Private
Development stage: Preclinical

Overview

IMMIOS is a newly established biotechnology company focused on developing new medicines at the intersection of immunology and oncology. The company aims to translate cutting-edge science into innovative therapeutics for autoimmune diseases and cancer. No clinical results have been published yet as they appear to be in an early stage

Therapeutic areas: OncologyImmunology
Modalities: Not explicitly stated; likely includes biologics or novel therapeutics at the interface of immunology and oncology
Industry: Biotech

Beyond the preview

Go deeper on IMMIOS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMMIOS.

Explore the full profile